The Global Urea Breath Test Market, by Test Type (Point-of-Care Tests (POCT) and Laboratory Based Test), by Product (Breath Analyzer and UBT-Kits), by Instrument (Mass Spectrometer, Infrared Spectrometer, and Laser Assisted Rationalizer), by End User (Hospitals, Clinics, and Diagnostic Centers (Standalone Labs and Private Lab Networks)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 115.96 million in 2022 and expected to exhibit a CAGR of 5.4% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Helicobacter pylori is a gram-negative, curved rod shaped bacterium, which is associated with peptic ulcer and other digestive system diseases. Researchers indicated that H. pylori infection spread from East Africa about 58,000 years ago and subsequently developed into many strains with varied degrees of pathogenicity.
There are various factors such as region, age, race, and socio-economic statuses which affect the prevalence of the H. pylori bacterium infection. However, in general, the prevalence in emerging countries is around 50.8%, whereas the prevalence is about 34.7% in the developed countries.
Based on Gastroenterology & Hepatology paper published in 2020, the prevalence of H. pylori bacterium infection was notably high in African region. According to the WHO recent studies concluded that in 2020 the prevalence was 80% in Nigeria and in 2017, it was 88% in Ghana.
The high prevalence of H. pylori bacterium infection in emerging economies is mostly attributed to several factors such as poor sanitation, overcrowding, lack of safe drinking water, and poor housing conditions among others. Though the urea breath test (UBT) is considered as the first-line diagnosis tool for H. pylori, the limited access of UBT kits during the sampling phase in South Africa was slightly affected. However, to better understand the status of H. pylori infections in Nigeria and other African countries several government initiatives were undertaken which can be attributed as a driving factor for the urea breath test market in the region.
For instance, the Deutsche Forschungsgemeinschaft, a German research foundation, started an initiative in context with the German-African infectiology for studying the epidemiological situation of H. pylori in Africa. This involved a collaboration with eight hospitals in Nigeria and hospitals of Lagos & Munich for providing access to urea breath test and biopsy examinations for efficient diagnosis of H. pylori in the population.
Global Urea Breath Test Market – COVID-19 Impact (Impact on Manufacturing)
The increasing prevalence of COVID-19 has caused production facilities to shutdown in almost all sectors, and also affected the supply of raw materials and medical devices of manufacturing companies across the globe.
Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of medical devices to avoid the spread of COVID-19. For instance, The European Commission adopted a proposal on April 3, 2020, to postpone the application date of the medical device regulation (MDR) for one year due to the COVID-19 pandemic. The functionality of the European Database on Medical Devices (EUDAMED) was announced on May 26, 2021, based on this proposal. Among the most significant changes brought about by European Union MDR were: increased clinical evaluation requirements, post-market surveillance (PMS), digital and physical labeling, and total life cycle traceability.
Browse 36 Market Data Tables and 40 Figures spread through 244 Pages and in-depth TOC on “Urea Breath Test Market”- Global Forecast to 2030, by Test Type (Point-of-Care Tests (POCT) and Laboratory Based Test), by Product (Breath Analyzer and UBT-Kits), by Instrument (Mass Spectrometer, Infrared Spectrometer, and Laser Assisted Rationalizer), by End User (Hospitals, Clinics, and Diagnostic Centers (Standalone Labs and Private Lab Networks)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Urea Breath Test Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/urea-breath-test-market-4645
The increasing number of test launches is expected to drive the growth of the market over the forecast period
For instance, in August 2017, Exalenz Bioscience, a subsidiary of Meridian Bioscience Inc., announced the expansion of its BreathID Hp urea breath testing product line by introducing the new BreathID Hp Lab. BreathID Hp provides real-time results and enables providers to test and treat at Point-of-Care tests (POCT).
Key Takeaways of the Global Urea Breath Test Market:
- The global urea breath test market is expected to exhibit a CAGR of 5.4% over the forecast period, owing to increasing lunches of product. For instance, in November 2019, Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company, announced the launch of POConePlus Infrared Spectrophotometer for the diagnosis of H.pylori (Helicobacter pylori) in Japan.
- Among Test Type, the laboratory based test is expected to account for the largest market share in 2022, owing to increasing inorganic growth activities such as acquisition, by market players are expected to drive the market growth over the forecast period. For instance, on July 31, 2021, Meridian Bioscience, Inc., a manufacturing company of diagnostic test kits and others, announced the acquisition of BreathTek UBT for H. pylori test from Otsuka America Pharmaceutical, a company that develops pharmaceuticals. The aim of this acquisition is to strengthen the company’s product portfolio in the global market.
- Key players operating in the global urea breath test market include Kibion AB (Mayoly Spindler), Avanos Medical, Inc., Quest Diagnostics, Beijing Richen-Force Science & Technology Co., Ltd., Paladin Labs Inc., Beijing Binal Health Bio- Sci & Tech Co., Ltd., AB ANALITICA s.r.l., Otsuka Holdings Co., Ltd., Sercon Group, Campro Scientific GmbH, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., Avisa Diagnostics, INFAI GmbH, Meridian Bioscience, Inc., Metabolic Solutions, Inc., Laboratory Corporation of America Holdings, , Gulf Coast Scientific, Inc., FAN GmbH, and Kizlon Medical
